Page 97 - 2026 SMOG

ACETYLSALICYLIC ACID (ASPIRIN)
Class/Mechanism of Action
• Nonsteroidal Anti-inflammatory Drug (NSAID)
Blocks cyclooxygenase (COX-1 and COX-2) enzymes, resulting in reduced formation of
prostaglandin precursors. Blocks formation of prostaglandin derivative, thromboxane A2,
resulting in inhibited platelet aggregation. Has antipyretic, analgesic, and anti-inflammatory
properties.
Indications
• Labeled Indications
˚ Treatment of acute coronary syndromes (ST-Elevation MI, Non-ST-Elevation MI, unstable
angina), acute ischemic stroke, and transient ischemic episodes
Contraindications
• Hypersensitivity to salicylates, other NSAIDs, or any component of the formulation
• Asthma, rhinitis
• Inherited or acquired bleeding disorders (including factor VII and factor IX deficiency)
• Do not use in children under 16 years old (Reye’s syndrome)
Adverse Reactions/Precautions
• Not for use on trauma patients in the combat environment
• Risk of bleeding. Avoid use in patients with known or suspected: Bleeding disorders, GI
bleed, GI ulcers, patients taking Coumadin, or within 24hr of taking Alteplase (tPA) for
suspected stroke
• Pregnancy: Category C
• Lactation: Yes, short-term or low dose OK
Dose/Administration
PEDIATRIC
ADULT
(Always reference Broselow Tape)
Acute Coronary Syndrome (ST-segment N/A
Elevation Myocardial Infarction [STEMI], • Contraindicated in children under
Unstable Angina (UA)/Non-ST-Segment 16 years (Reye’s Syndrome)
Elevation Myocardial Infarction [NSTEMI])
(Not for use in trauma patients)
• PO
˚ 162–325mg (chew nonenteric-coated
aspirin as a single 325mg tablet or four
81mg chewable tablets

2026 Standard Medical Operating Guidelines (SMOG) • 89